{"id":"W2164777416","doi":"10.1016/s1470-2045(15)00041-8","title":"Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":152,"is_retracted":false,"has_abstract":false,"ca_institutions":"Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute","keywords":"Medicine; Docetaxel; Bevacizumab; Capecitabine; Clinical endpoint; Neoadjuvant therapy; Internal medicine; Oncology; Breast cancer; Gemcitabine; Cyclophosphamide; Taxane; Chemotherapy; Surgery; Cancer; Clinical trial; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003589519,0.002577994,0.003755362,0.0004667262,0.0005339933,0.001489076,0.0009408954,0.002150185,0.005676923],"category_scores_gemma":[0.003952494,0.0007767011,0.003674504,0.0006501814,0.001331941,0.001414163,0.0006503001,0.004213035,0.00106074],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001410435,"about_ca_system_score_gemma":0.001410892,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001964828,"about_ca_topic_score_gemma":0.004099059,"domain_scores_codex":[0.9980918,0.001216148,0.0001315054,0.00023739,0.0001114117,0.0002118985],"domain_scores_gemma":[0.9978683,0.0007382042,0.0006458183,0.0001610114,0.0001438733,0.0004428551],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9905212,0.001121483,0.0004039701,0.0006690153,0.001978412,0.00001517059,0.00002256715,0.0001608885,0.0006079902,0.00005539991,0.0004796116,0.003964301],"study_design_scores_gemma":[0.9703648,0.02479408,0.001558008,0.00007264016,0.002095533,0.00002095859,0.00002008439,0.0001881487,0.0001800866,0.0001937838,0.0004973478,0.00001446394],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9682482,0.01662139,0.001242397,0.001792444,0.001277015,0.00452741,0.002789955,0.0001445581,0.003356633],"genre_scores_gemma":[0.9783189,0.006028701,0.001926215,0.001628101,0.0007374008,0.005640759,0.002037963,0.00004150374,0.003640433],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005676923,"threshold_uncertainty_score":0.01899123,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0375631773273734,"score_gpt":0.3579532375713889,"score_spread":0.3203900602440155,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}